 |
 |
 |
 |
 |
 |
 |
 |
 |
Zidovudine/Lamivudine/Abacavir (Trizivir)
Overview
- A Clinical Overview of Zidovudine/Lamivudine/Abacavir (Trizivir) (Regularly Updated)
From AIDSinfo - Prescribing Information for Zidovudine/Lamivudine/Abacavir (Trizivir) (PDF) (March 2009)
From GlaxoSmithKline
Research
- Literature Citations for Trizivir (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Trizivir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Trizivir Preferred Over Continued HAART in HIV-Infected Patients (March/April 2002)
TRIZAL study results; highlights from ICAAC 2002.
In Body Positive, from Body Positive - Comparison of the Metabolic Disorders and Clinical Lipodystrophy 48 Weeks After Switching From HAART to Trizivir Versus Continued HAART (TRIZAL: AZL30002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Clinical Management
Clinical Management
  |